H.C. Wainwright Remains a Buy on Coherus Biosciences (CHRS)
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Douglas Tsao maintains a Buy rating on Coherus Biosciences with a $7.00 price target. Tsao, a 5-star analyst, has a 22.0% average return and 53.85% success rate. Maxim Group also issued a Buy rating, while TR | OpenAI reiterated a Hold rating. Tsao covers the Healthcare sector, focusing on stocks like Protagonist Therapeutics and Alkermes.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments